Rheumatoid Arthritis Biosimilar Meets Equivalency Endpoints in Phase 1/3 Trial - Specialty Pharmacy Times

Rheumatoid Arthritis Biosimilar Meets Equivalency Endpoints in Phase 1/3 Trial  Specialty Pharmacy Times

Topline results from a phase 1/phase 3 clinical trial of ABP 798 in patients with moderate-to-severe rheumatoid arthritis have been released. ABP 798 is a ...